The ‘Trastuzumab for Gastric Cancer’ (ToGA) trial was a phase III, open-label, RCT comparing trastuzumab with platinum-based chemotherapy against chemotherapy alone as a first-line treatment for advanced GC with HER2 overexpression or amplification (Bang et al, 2010). The gene discussed is ERBB2; the disease is gastric cancer.